Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	chromatin binding	FOXA1 NCOA2 NFAT5 NIPBL EP300 KAT6A	1.47e-05	739	16	6	GO:0003682
GeneOntologyMolecularFunction	histone H3 acetyltransferase activity	EP300 KAT6A	6.28e-05	15	16	2	GO:0010484
GeneOntologyMolecularFunction	nuclear glucocorticoid receptor binding	NCOA2 EP300	1.13e-04	20	16	2	GO:0035259
GeneOntologyMolecularFunction	histone H4 acetyltransferase activity	EP300 KAT6A	1.51e-04	23	16	2	GO:0010485
GeneOntologyMolecularFunction	transcription factor binding	FOXA1 NCOA2 NFAT5 EP300 KAT6A	2.32e-04	753	16	5	GO:0008134
GeneOntologyMolecularFunction	RNA polymerase II cis-regulatory region sequence-specific DNA binding	FOXA1 NCOA2 PKNOX2 NFAT5 EP300 NR1D2	2.69e-04	1244	16	6	GO:0000978
GeneOntologyMolecularFunction	cis-regulatory region sequence-specific DNA binding	FOXA1 NCOA2 PKNOX2 NFAT5 EP300 NR1D2	3.02e-04	1271	16	6	GO:0000987
GeneOntologyMolecularFunction	protein domain specific binding	FOXA1 NCOA2 NIPBL CHMP2B SON	4.66e-04	875	16	5	GO:0019904
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	FOXA1 NCOA2 PKNOX2 NFAT5 EP300 NR1D2	6.36e-04	1459	16	6	GO:0000977
GeneOntologyMolecularFunction	histone acetyltransferase activity	EP300 KAT6A	7.50e-04	51	16	2	GO:0004402
GeneOntologyMolecularFunction	transcription coregulator activity	NCOA2 NIPBL EP300 KAT6A	8.63e-04	562	16	4	GO:0003712
GeneOntologyMolecularFunction	peptide-lysine-N-acetyltransferase activity	EP300 KAT6A	8.72e-04	55	16	2	GO:0061733
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	FOXA1 NCOA2 EP300 KAT6A	9.83e-04	582	16	4	GO:0140297
GeneOntologyMolecularFunction	peptide N-acetyltransferase activity	EP300 KAT6A	1.04e-03	60	16	2	GO:0034212
GeneOntologyMolecularFunction	transcription coactivator activity	NCOA2 EP300 KAT6A	1.67e-03	303	16	3	GO:0003713
GeneOntologyMolecularFunction	N-acetyltransferase activity	EP300 KAT6A	1.74e-03	78	16	2	GO:0008080
GeneOntologyMolecularFunction	promoter-specific chromatin binding	NIPBL EP300	1.97e-03	83	16	2	GO:1990841
GeneOntologyMolecularFunction	N-acyltransferase activity	EP300 KAT6A	2.96e-03	102	16	2	GO:0016410
GeneOntologyMolecularFunction	acetyltransferase activity	EP300 KAT6A	3.07e-03	104	16	2	GO:0016407
GeneOntologyMolecularFunction	RNA polymerase II-specific DNA-binding transcription factor binding	FOXA1 NCOA2 EP300	4.14e-03	417	16	3	GO:0061629
GeneOntologyMolecularFunction	nuclear receptor binding	NCOA2 EP300	9.60e-03	187	16	2	GO:0016922
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	NCOA2 NIPBL EP300 KAT6A	1.18e-02	1160	16	4	GO:0030674
GeneOntologyMolecularFunction	histone modifying activity	EP300 KAT6A	1.41e-02	229	16	2	GO:0140993
GeneOntologyMolecularFunction	acyltransferase activity, transferring groups other than amino-acyl groups	EP300 KAT6A	1.52e-02	238	16	2	GO:0016747
GeneOntologyMolecularFunction	molecular adaptor activity	NCOA2 NIPBL EP300 KAT6A	1.99e-02	1356	16	4	GO:0060090
GeneOntologyBiologicalProcess	face morphogenesis	NIPBL EP300 KAT6A	4.01e-06	41	16	3	GO:0060325
GeneOntologyBiologicalProcess	head morphogenesis	NIPBL EP300 KAT6A	6.48e-06	48	16	3	GO:0060323
GeneOntologyBiologicalProcess	positive regulation of hydrogen peroxide-mediated programmed cell death	FOXA1 EP300	1.18e-05	7	16	2	GO:1901300
GeneOntologyBiologicalProcess	face development	NIPBL EP300 KAT6A	1.48e-05	63	16	3	GO:0060324
GeneOntologyBiologicalProcess	body morphogenesis	NIPBL EP300 KAT6A	1.55e-05	64	16	3	GO:0010171
GeneOntologyBiologicalProcess	hormone-mediated signaling pathway	FOXA1 NCOA2 EP300 NR1D2	3.11e-05	244	16	4	GO:0009755
GeneOntologyBiologicalProcess	chromatin organization	FOXA1 NFAT5 LAMC1 NIPBL EP300 KAT6A	3.64e-05	896	16	6	GO:0006325
GeneOntologyBiologicalProcess	regulation of intracellular steroid hormone receptor signaling pathway	FOXA1 NCOA2 EP300	3.90e-05	87	16	3	GO:0033143
GeneOntologyBiologicalProcess	protein-DNA complex organization	FOXA1 NFAT5 LAMC1 NIPBL EP300 KAT6A	6.70e-05	999	16	6	GO:0071824
GeneOntologyBiologicalProcess	positive regulation of intracellular steroid hormone receptor signaling pathway	FOXA1 NCOA2	8.57e-05	18	16	2	GO:0033145
GeneOntologyBiologicalProcess	regulation of hydrogen peroxide-mediated programmed cell death	FOXA1 EP300	9.57e-05	19	16	2	GO:1901298
GeneOntologyBiologicalProcess	hydrogen peroxide-mediated programmed cell death	FOXA1 EP300	1.29e-04	22	16	2	GO:0010421
GeneOntologyBiologicalProcess	nuclear receptor-mediated steroid hormone signaling pathway	FOXA1 NCOA2 EP300	1.47e-04	136	16	3	GO:0030518
GeneOntologyBiologicalProcess	programmed cell death in response to reactive oxygen species	FOXA1 EP300	1.54e-04	24	16	2	GO:0097468
GeneOntologyBiologicalProcess	chromatin remodeling	FOXA1 NFAT5 NIPBL EP300 KAT6A	1.85e-04	741	16	5	GO:0006338
GeneOntologyBiologicalProcess	steroid hormone receptor signaling pathway	FOXA1 NCOA2 EP300	2.17e-04	155	16	3	GO:0043401
GeneOntologyBiologicalProcess	intracellular receptor signaling pathway	FOXA1 NCOA2 EP300 NR1D2	2.45e-04	416	16	4	GO:0030522
GeneOntologyBiologicalProcess	animal organ morphogenesis	FOXA1 LAMC1 NIPBL EP300 RYR2 KAT6A	2.51e-04	1269	16	6	GO:0009887
GeneOntologyBiologicalProcess	cognition	NIPBL EP300 HMGCR CHMP2B	2.61e-04	423	16	4	GO:0050890
GeneOntologyBiologicalProcess	muscle organ development	EP300 HMGCR RYR2 NR1D2	2.93e-04	436	16	4	GO:0007517
GeneOntologyBiologicalProcess	muscle structure development	LAMC1 EP300 HMGCR RYR2 NR1D2	3.66e-04	858	16	5	GO:0061061
GeneOntologyBiologicalProcess	positive regulation of transcription by RNA polymerase II	FOXA1 NCOA2 NFAT5 NIPBL EP300 NR1D2	4.12e-04	1390	16	6	GO:0045944
GeneOntologyBiologicalProcess	negative regulation of DNA-templated transcription	FOXA1 NCOA2 NIPBL EP300 NR1D2 KAT6A	4.27e-04	1399	16	6	GO:0045892
GeneOntologyBiologicalProcess	negative regulation of RNA biosynthetic process	FOXA1 NCOA2 NIPBL EP300 NR1D2 KAT6A	4.50e-04	1413	16	6	GO:1902679
GeneOntologyBiologicalProcess	nuclear receptor-mediated signaling pathway	FOXA1 NCOA2 EP300	4.72e-04	202	16	3	GO:0141193
GeneOntologyBiologicalProcess	embryo development	FOXA1 NIPBL EP300 HMGCR RYR2 KAT6A	4.93e-04	1437	16	6	GO:0009790
GeneOntologyBiologicalProcess	skeletal muscle tissue development	EP300 HMGCR NR1D2	6.29e-04	223	16	3	GO:0007519
GeneOntologyBiologicalProcess	muscle tissue development	EP300 HMGCR RYR2 NR1D2	7.44e-04	558	16	4	GO:0060537
GeneOntologyBiologicalProcess	cellular response to steroid hormone stimulus	FOXA1 NCOA2 EP300	7.70e-04	239	16	3	GO:0071383
GeneOntologyBiologicalProcess	skeletal muscle organ development	EP300 HMGCR NR1D2	7.79e-04	240	16	3	GO:0060538
GeneOntologyBiologicalProcess	positive regulation of cell adhesion	FOXA1 NFAT5 LAMC1 EP300	8.55e-04	579	16	4	GO:0045785
GeneOntologyBiologicalProcess	circadian rhythm	NCOA2 EP300 NR1D2	8.57e-04	248	16	3	GO:0007623
GeneOntologyBiologicalProcess	negative regulation of transcription by RNA polymerase II	FOXA1 NCOA2 NIPBL EP300 NR1D2	9.35e-04	1053	16	5	GO:0000122
GeneOntologyBiologicalProcess	cellular response to organic cyclic compound	FOXA1 NCOA2 EP300 RYR2	1.01e-03	605	16	4	GO:0071407
GeneOntologyBiologicalProcess	protein acetylation	EP300 KAT6A	1.25e-03	68	16	2	GO:0006473
GeneOntologyBiologicalProcess	circadian behavior	NCOA2 NR1D2	1.36e-03	71	16	2	GO:0048512
GeneOntologyBiologicalProcess	rhythmic behavior	NCOA2 NR1D2	1.47e-03	74	16	2	GO:0007622
GeneOntologyCellularComponent	chromatin	FOXA1 NCOA2 NFAT5 NIPBL EP300 NR1D2 KAT6A	5.69e-05	1480	16	7	GO:0000785
GeneOntologyCellularComponent	histone acetyltransferase complex	EP300 KAT6A	2.30e-03	94	16	2	GO:0000123
GeneOntologyCellularComponent	protein acetyltransferase complex	EP300 KAT6A	2.81e-03	104	16	2	GO:0031248
GeneOntologyCellularComponent	acetyltransferase complex	EP300 KAT6A	3.08e-03	109	16	2	GO:1902493
MousePheno	atrial septal defect	NIPBL EP300 NR1D2 KAT6A	2.52e-06	88	16	4	MP:0010403
MousePheno	abnormal interatrial septum morphology	NIPBL EP300 NR1D2 KAT6A	5.50e-06	107	16	4	MP:0000282
MousePheno	abnormal interventricular septum morphology	NIPBL EP300 RYR2 NR1D2 KAT6A	2.98e-05	342	16	5	MP:0000281
MousePheno	abnormal heart septum morphology	NIPBL EP300 RYR2 NR1D2 KAT6A	5.45e-05	388	16	5	MP:0006113
MousePheno	abnormal myocardium compact layer morphology	NFAT5 NIPBL EP300	5.64e-05	67	16	3	MP:0004056
MousePheno	abnormal heart atrium morphology	NIPBL EP300 NR1D2 KAT6A	1.15e-04	232	16	4	MP:0003105
MousePheno	abnormal atrioventricular septum morphology	EP300 NR1D2 KAT6A	1.23e-04	87	16	3	MP:0010592
MousePheno	abnormal heart ventricle morphology	NFAT5 NIPBL EP300 RYR2 NR1D2 KAT6A	1.60e-04	793	16	6	MP:0005294
MousePheno	abnormal epicardium morphology	EP300 RYR2	1.65e-04	17	16	2	MP:0003057
MousePheno	ventricular septal defect	NIPBL EP300 NR1D2 KAT6A	1.81e-04	261	16	4	MP:0010402
MousePheno	abnormal fetal growth/weight/body size	LAMC1 NIPBL RYR2 KAT6A	3.58e-04	312	16	4	MP:0004197
MousePheno	abnormal myocardial trabeculae morphology	NFAT5 EP300 RYR2	5.43e-04	144	16	3	MP:0002189
Domain	Nuc_rcpt_coact	NCOA2 EP300	1.03e-05	6	16	2	IPR009110
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	FOXA1 NCOA2 EP300	2.36e-05	63	13	3	MM15613
Pathway	PID_SMAD2_3NUCLEAR_PATHWAY	NCOA2 LAMC1 EP300	5.20e-05	82	13	3	M2
Pathway	REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	NCOA2 EP300	1.19e-04	18	13	2	M26942
Pathway	REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA	NCOA2 EP300 HMGCR	1.54e-04	118	13	3	M27316
Pathway	REACTOME_ESR_MEDIATED_SIGNALING	FOXA1 NCOA2 EP300	2.19e-04	133	13	3	MM15529
Pathway	REACTOME_HATS_ACETYLATE_HISTONES	NCOA2 EP300 KAT6A	2.66e-04	142	13	3	M27233
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	FOXA1 NCOA2 EP300	3.06e-04	149	13	3	M27888
Pathway	REACTOME_EGR2_AND_SOX10_MEDIATED_INITIATION_OF_SCHWANN_CELL_MYELINATION	LAMC1 HMGCR	3.14e-04	29	13	2	M29808
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	EP300 KAT6A	3.14e-04	29	13	2	MM15340
Pathway	PID_RETINOIC_ACID_PATHWAY	NCOA2 EP300	3.37e-04	30	13	2	M207
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	EP300 KAT6A	3.37e-04	30	13	2	M27637
Pathway	REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS	FOXA1 NCOA2 EP300	6.34e-04	191	13	3	MM15586
Pathway	REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP	NCOA2 HMGCR	6.62e-04	42	13	2	M27172
Pathway	PID_HNF3A_PATHWAY	FOXA1 EP300	7.27e-04	44	13	2	M285
Pathway	REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	NCOA2 EP300	7.27e-04	44	13	2	M27295
Pathway	WP_CIRCADIAN_RHYTHM_GENES	NCOA2 EP300 NR1D2	7.35e-04	201	13	3	M39605
Pathway	REACTOME_HATS_ACETYLATE_HISTONES	NCOA2 KAT6A	7.94e-04	46	13	2	MM14935
Pathway	REACTOME_HEME_SIGNALING	NCOA2 EP300	9.01e-04	49	13	2	M41832
Pathway	REACTOME_ESR_MEDIATED_SIGNALING	FOXA1 NCOA2 EP300	9.55e-04	220	13	3	M27794
Pathway	PID_AR_TF_PATHWAY	NCOA2 EP300	1.05e-03	53	13	2	M151
Pathway	REACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF	NCOA2 HMGCR	1.13e-03	55	13	2	M27001
Pathway	WP_SIDS_SUSCEPTIBILITY_PATHWAYS	EP300 RYR2	1.30e-03	59	13	2	MM15838
Pathway	PID_ERA_GENOMIC_PATHWAY	NCOA2 EP300	1.53e-03	64	13	2	M200
Pathway	WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	EP300 KAT6A	1.58e-03	65	13	2	M39682
Pathway	PID_HIF1_TFPATHWAY	NCOA2 EP300	1.63e-03	66	13	2	M255
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	NCOA2 EP300 KAT6A	1.76e-03	272	13	3	M29619
Pathway	REACTOME_CIRCADIAN_CLOCK	NCOA2 EP300	1.83e-03	70	13	2	M938
Pathway	REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS	FOXA1 NCOA2 EP300	2.24e-03	296	13	3	M27869
Pathway	PID_BETA_CATENIN_NUC_PATHWAY	NCOA2 EP300	2.38e-03	80	13	2	M223
Pathway	PID_REG_GR_PATHWAY	NCOA2 EP300	2.50e-03	82	13	2	M115
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION	NCOA2 EP300	2.62e-03	84	13	2	M1008
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	NCOA2 EP300	3.07e-03	91	13	2	M39700
Pubmed	Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.	FOXA1 NCOA2 EP300	5.41e-08	17	16	3	19183483
Pubmed	A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.	NCOA2 KAT6A	1.98e-07	2	16	2	9558366
Pubmed	Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.	NCOA2 KAT6A	1.98e-07	2	16	2	26854485
Pubmed	MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).	EP300 KAT6A	1.98e-07	2	16	2	10824998
Pubmed	MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.	NCOA2 KAT6A	5.95e-07	3	16	2	12676584
Pubmed	Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities.	NCOA2 EP300	1.19e-06	4	16	2	11997499
Pubmed	MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.	NCOA2 KAT6A	1.19e-06	4	16	2	16613851
Pubmed	LPS-induced NFκB enhanceosome requires TonEBP/NFAT5 without DNA binding.	NFAT5 EP300	1.19e-06	4	16	2	27118681
Pubmed	Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling.	NCOA2 EP300	1.19e-06	4	16	2	20448036
Pubmed	Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.	NCOA2 KAT6A	1.19e-06	4	16	2	24258712
Pubmed	A simple method to screen ligands of peroxisome proliferator-activated receptor delta.	NCOA2 EP300	1.19e-06	4	16	2	16930961
Pubmed	MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.	NCOA2 KAT6A	1.19e-06	4	16	2	17697320
Pubmed	Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication.	EP300 KAT6A	1.98e-06	5	16	2	17182677
Pubmed	Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.	NCOA2 EP300	1.98e-06	5	16	2	16645043
Pubmed	SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4.	NCOA2 EP300	1.98e-06	5	16	2	9812974
Pubmed	MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.	NCOA2 KAT6A	1.98e-06	5	16	2	15657427
Pubmed	Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.	NCOA2 EP300	1.98e-06	5	16	2	12714702
Pubmed	Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300/CBP and HBO1.	EP300 KAT6A	1.98e-06	5	16	2	26625199
Pubmed	New nomenclature for chromatin-modifying enzymes.	NCOA2 EP300 KAT6A	2.30e-06	57	16	3	18022353
Pubmed	TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.	FOXA1 NCOA2 EP300 SON	2.67e-06	220	16	4	35785414
Pubmed	MOZ is essential for maintenance of hematopoietic stem cells.	EP300 KAT6A	2.97e-06	6	16	2	16702405
Pubmed	Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest.	EP300 KAT6A	2.97e-06	6	16	2	19001415
Pubmed	Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly.	NCOA2 EP300	2.97e-06	6	16	2	16923966
Pubmed	Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination.	NCOA2 EP300	2.97e-06	6	16	2	15731352
Pubmed	Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex.	NCOA2 EP300	4.16e-06	7	16	2	9590696
Pubmed	An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors.	NCOA2 EP300	4.16e-06	7	16	2	9920895
Pubmed	The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine.	NCOA2 EP300	4.16e-06	7	16	2	12709428
Pubmed	The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment.	NCOA2 EP300	5.55e-06	8	16	2	12082103
Pubmed	Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu.	NCOA2 EP300	5.55e-06	8	16	2	14747462
Pubmed	Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.	NCOA2 EP300	5.55e-06	8	16	2	10490106
Pubmed	Regulation of somatic growth by the p160 coactivator p/CIP.	NCOA2 EP300	7.13e-06	9	16	2	11087842
Pubmed	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.	NCOA2 NIPBL EP300	7.18e-06	83	16	3	28794006
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	NCOA2 LAMC1 NIPBL EP300 RYR2	7.55e-06	638	16	5	31182584
Pubmed	A transcriptional inhibitor targeted by the atypical orphan nuclear receptor SHP.	NCOA2 EP300	8.91e-06	10	16	2	11964378
Pubmed	The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor α target genes.	FOXA1 EP300	8.91e-06	10	16	2	25223786
Pubmed	Acetylation of HIV-1 integrase by p300 regulates viral integration.	EP300 KAT6A	1.09e-05	11	16	2	16096645
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	FOXA1 NCOA2 PKNOX2 NFAT5 NR1D2	1.26e-05	709	16	5	22988430
Pubmed	The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.	LAMC1 EP300 KAT6A SON	1.36e-05	332	16	4	37433992
Pubmed	Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.	NCOA2 EP300	1.80e-05	14	16	2	11500849
Pubmed	Cohesin regulates tissue-specific expression by stabilizing highly occupied cis-regulatory modules.	FOXA1 EP300	2.37e-05	16	16	2	22780989
Pubmed	A genome wide association study identifies common variants associated with lipid levels in the Chinese population.	HMGCR RYR2	2.69e-05	17	16	2	24386095
Pubmed	EDAG positively regulates erythroid differentiation and modifies GATA1 acetylation through recruiting p300.	EP300 KAT6A	3.02e-05	18	16	2	24740910
Pubmed	Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/β-catenin, and mTOR signaling during corticogenesis.	NIPBL EP300	3.02e-05	18	16	2	33323119
Pubmed	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.	NCOA2 EP300	3.75e-05	20	16	2	11877444
Pubmed	Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.	NCOA2 EP300	4.15e-05	21	16	2	19596656
Pubmed	Differential expression and function of ABCG1 and ABCG4 during development and aging.	FOXA1 HMGCR	4.56e-05	22	16	2	19633360
Pubmed	Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells.	FOXA1 NCOA2	4.99e-05	23	16	2	19737349
Pubmed	Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action.	NCOA2 EP300	7.45e-05	28	16	2	24880616
Pubmed	Tangential Intrahypothalamic Migration of the Mouse Ventral Premamillary Nucleus and Fgf8 Signaling.	FOXA1 PKNOX2	9.16e-05	31	16	2	34095148
Pubmed	Impact of cytosine methylation on DNA binding specificities of human transcription factors.	FOXA1 PKNOX2 NFAT5 NR1D2	9.28e-05	544	16	4	28473536
Pubmed	Substrate and functional diversity of lysine acetylation revealed by a proteomics survey.	EP300 KAT6A SON	1.04e-04	203	16	3	16916647
Pubmed	Phosphoproteome analysis of the human mitotic spindle.	NIPBL CHMP2B SON	1.15e-04	210	16	3	16565220
Pubmed	Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1.	FOXA1 EP300	1.53e-04	40	16	2	34585037
Pubmed	Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation.	NCOA2 LAMC1 NIPBL EP300 HMGCR	1.63e-04	1215	16	5	15146197
Pubmed	Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.	NCOA2 EP300 HMGCR	1.92e-04	250	16	3	18660489
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	FOXA1 NCOA2 NIPBL	2.35e-04	268	16	3	33640491
Pubmed	Homologs of genes expressed in Caenorhabditis elegans GABAergic neurons are also found in the developing mouse forebrain.	FOXA1 KAT6A	3.12e-04	57	16	2	21122108
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	NCOA2 PKNOX2 NFAT5 EP300 KAT6A	4.20e-04	1489	16	5	28611215
Pubmed	Chemical Crosslinking Mass Spectrometry Analysis of Protein Conformations and Supercomplexes in Heart Tissue.	RYR2 KAT6A SON	4.36e-04	331	16	3	29199018
Interaction	TLE3 interactions	FOXA1 NCOA2 NIPBL EP300 SON	8.12e-06	376	16	5	int:TLE3
Interaction	TLX1 interactions	NCOA2 NIPBL EP300 KAT6A	9.22e-06	175	16	4	int:TLX1
Interaction	CGGBP1 interactions	FOXA1 EP300 KAT6A	9.94e-06	54	16	3	int:CGGBP1
Interaction	DDX47 interactions	FOXA1 NIPBL EP300 KAT6A	1.17e-05	186	16	4	int:DDX47
Interaction	NFIA interactions	FOXA1 NCOA2 EP300 SON	1.22e-05	188	16	4	int:NFIA
Interaction	PSIP1 interactions	FOXA1 EP300 KAT6A SON	1.72e-05	205	16	4	int:PSIP1
Interaction	RBM17 interactions	FOXA1 EP300 KAT6A SON	2.19e-05	218	16	4	int:RBM17
Interaction	ASCC1 interactions	FOXA1 EP300 KAT6A	2.27e-05	71	16	3	int:ASCC1
Interaction	SRPK1 interactions	FOXA1 LAMC1 EP300 KAT6A SON	2.56e-05	477	16	5	int:SRPK1
Interaction	PRPF3 interactions	FOXA1 EP300 KAT6A SON	6.76e-05	291	16	4	int:PRPF3
Interaction	PAX8 interactions	NCOA2 NIPBL EP300	8.64e-05	111	16	3	int:PAX8
Interaction	TBXT interactions	NCOA2 NIPBL EP300	9.85e-05	116	16	3	int:TBXT
Interaction	PRPF6 interactions	FOXA1 EP300 KAT6A SON	1.18e-04	336	16	4	int:PRPF6
Interaction	KLF13 interactions	EP300 KAT6A	1.23e-04	21	16	2	int:KLF13
Interaction	YAP1 interactions	FOXA1 PKNOX2 NFAT5 EP300 CLINT1 CHMP2B	1.27e-04	1095	16	6	int:YAP1
Interaction	PAX9 interactions	NCOA2 NIPBL EP300	1.38e-04	130	16	3	int:PAX9
Interaction	SSRP1 interactions	FOXA1 NIPBL EP300 KAT6A SON	1.43e-04	685	16	5	int:SSRP1
Interaction	AHR interactions	FOXA1 NCOA2 EP300	1.45e-04	132	16	3	int:AHR
Interaction	CBX5 interactions	FOXA1 NIPBL EP300 KAT6A	1.47e-04	356	16	4	int:CBX5
Interaction	DCAF7 interactions	FOXA1 NIPBL EP300 HMGCR	1.67e-04	368	16	4	int:DCAF7
Interaction	SETSIP interactions	EP300 KAT6A	1.75e-04	25	16	2	int:SETSIP
Interaction	NCOA6 interactions	FOXA1 NCOA2 EP300	1.91e-04	145	16	3	int:NCOA6
Interaction	MEX3A interactions	LAMC1 EP300 KAT6A SON	1.97e-04	384	16	4	int:MEX3A
Interaction	PHGDH interactions	MS4A4A EP300 CHMP2B SON	1.99e-04	385	16	4	int:PHGDH
Interaction	H4C16 interactions	NCOA2 EP300 KAT6A	2.19e-04	152	16	3	int:H4C16
Interaction	ETV1 interactions	NCOA2 EP300	2.37e-04	29	16	2	int:ETV1
Interaction	DLX5 interactions	FOXA1 NCOA2	2.37e-04	29	16	2	int:DLX5
Interaction	C19orf53 interactions	FOXA1 KAT6A	2.37e-04	29	16	2	int:C19orf53
Interaction	NRIP1 interactions	FOXA1 NCOA2 PKNOX2	3.05e-04	170	16	3	int:NRIP1
Interaction	EGR2 interactions	NCOA2 NIPBL EP300	3.10e-04	171	16	3	int:EGR2
Interaction	H3-4 interactions	FOXA1 NCOA2 EP300 KAT6A	3.55e-04	448	16	4	int:H3-4
Interaction	HNF1B interactions	NCOA2 NIPBL EP300	4.22e-04	190	16	3	int:HNF1B
Interaction	JUN interactions	NCOA2 NFAT5 EP300 CLINT1	4.25e-04	470	16	4	int:JUN
Interaction	RORA interactions	NCOA2 EP300	4.30e-04	39	16	2	int:RORA
Interaction	MYOD1 interactions	NCOA2 NIPBL EP300	4.48e-04	194	16	3	int:MYOD1
Interaction	SF3B6 interactions	FOXA1 EP300 SON	4.48e-04	194	16	3	int:SF3B6
Interaction	KLF5 interactions	NCOA2 NIPBL EP300	4.55e-04	195	16	3	int:KLF5
Interaction	HOXB1 interactions	PKNOX2 EP300	4.76e-04	41	16	2	int:HOXB1
Interaction	TFF1 interactions	FOXA1 EP300	4.76e-04	41	16	2	int:TFF1
Interaction	NR5A2 interactions	FOXA1 NCOA2	4.76e-04	41	16	2	int:NR5A2
Interaction	EP300 interactions	NCOA2 EP300 HMGCR CLINT1 KAT6A SON	4.87e-04	1401	16	6	int:EP300
Interaction	MRTO4 interactions	FOXA1 EP300 KAT6A	4.90e-04	200	16	3	int:MRTO4
Interaction	FEV interactions	NCOA2 NIPBL EP300	5.12e-04	203	16	3	int:FEV
Interaction	RABGEF1 interactions	EP300 HMGCR CLINT1	5.19e-04	204	16	3	int:RABGEF1
Interaction	DPY30 interactions	FOXA1 KAT6A CHMP2B	5.19e-04	204	16	3	int:DPY30
Interaction	HEMGN interactions	EP300 KAT6A	5.48e-04	44	16	2	int:HEMGN
Interaction	C11orf98 interactions	FOXA1 KAT6A	5.48e-04	44	16	2	int:C11orf98
Interaction	DEK interactions	FOXA1 EP300 KAT6A	5.57e-04	209	16	3	int:DEK
Interaction	RORC interactions	EP300 NR1D2	5.74e-04	45	16	2	int:RORC
Interaction	NR1I2 interactions	NCOA2 EP300	6.53e-04	48	16	2	int:NR1I2
Interaction	ERG interactions	NCOA2 NIPBL EP300	6.73e-04	223	16	3	int:ERG
Interaction	NCOA3 interactions	FOXA1 NCOA2 EP300	6.82e-04	224	16	3	int:NCOA3
Interaction	XPO5 interactions	FOXA1 MS4A4A EP300	7.09e-04	227	16	3	int:XPO5
Interaction	NR3C1 interactions	NCOA2 LAMC1 NIPBL EP300 RYR2	7.29e-04	974	16	5	int:NR3C1
Interaction	CENPP interactions	PKNOX2 KAT6A	7.37e-04	51	16	2	int:CENPP
Interaction	EID1 interactions	NCOA2 EP300	7.37e-04	51	16	2	int:EID1
Interaction	NAA40 interactions	FOXA1 NIPBL CLINT1 CHMP2B SON	7.43e-04	978	16	5	int:NAA40
Interaction	AR interactions	FOXA1 NCOA2 NIPBL EP300 SON	7.93e-04	992	16	5	int:AR
Interaction	MEF2C interactions	NCOA2 EP300	8.26e-04	54	16	2	int:MEF2C
Interaction	LUC7L interactions	FOXA1 EP300 KAT6A	8.53e-04	242	16	3	int:LUC7L
Interaction	NKRF interactions	FOXA1 EP300 KAT6A	8.74e-04	244	16	3	int:NKRF
Interaction	SAFB interactions	FOXA1 EP300 SON	8.74e-04	244	16	3	int:SAFB
Interaction	LDB2 interactions	FOXA1 EP300	8.88e-04	56	16	2	int:LDB2
Interaction	MAD2L1 interactions	NCOA2 KAT6A CHMP2B	9.59e-04	252	16	3	int:MAD2L1
Interaction	RAB1B interactions	EP300 HMGCR CLINT1	9.70e-04	253	16	3	int:RAB1B
Interaction	CRX interactions	NCOA2 NIPBL EP300	9.81e-04	254	16	3	int:CRX
Interaction	CPSF1 interactions	NCOA2 EP300 KAT6A	9.92e-04	255	16	3	int:CPSF1
Interaction	DDX50 interactions	FOXA1 EP300 KAT6A	1.02e-03	257	16	3	int:DDX50
Interaction	BUD23 interactions	FOXA1 EP300	1.09e-03	62	16	2	int:BUD23
Interaction	MAGOH interactions	FOXA1 EP300 SON	1.10e-03	264	16	3	int:MAGOH
Interaction	RPL5 interactions	FOXA1 CLINT1 KAT6A SON	1.10e-03	606	16	4	int:RPL5
Interaction	MED23 interactions	NCOA2 NIPBL EP300	1.12e-03	266	16	3	int:MED23
Interaction	PRKAA1 interactions	EP300 HMGCR KAT6A	1.15e-03	268	16	3	int:PRKAA1
Interaction	HGH1 interactions	EP300 KAT6A	1.19e-03	65	16	2	int:HGH1
Interaction	HNF4A interactions	NCOA2 NIPBL EP300	1.23e-03	275	16	3	int:HNF4A
Interaction	NUP43 interactions	NIPBL RYR2 NR1D2 SON	1.24e-03	625	16	4	int:NUP43
Interaction	POP1 interactions	FOXA1 EP300 KAT6A	1.26e-03	277	16	3	int:POP1
Interaction	SLBP interactions	EP300 KAT6A	1.27e-03	67	16	2	int:SLBP
Interaction	SPI1 interactions	EP300 KAT6A	1.27e-03	67	16	2	int:SPI1
Interaction	ETV4 interactions	NCOA2 EP300	1.34e-03	69	16	2	int:ETV4
Interaction	RPL34 interactions	FOXA1 EP300 KAT6A	1.37e-03	285	16	3	int:RPL34
Interaction	ADAR interactions	FOXA1 NIPBL EP300	1.38e-03	286	16	3	int:ADAR
Interaction	SLC39A3 interactions	EP300 HMGCR	1.38e-03	70	16	2	int:SLC39A3
Interaction	SUMO1 interactions	FOXA1 NCOA2 EP300	1.39e-03	287	16	3	int:SUMO1
Interaction	FLNA interactions	NIPBL EP300 CLINT1 KAT6A	1.42e-03	648	16	4	int:FLNA
Interaction	NOL7 interactions	FOXA1 KAT6A	1.42e-03	71	16	2	int:NOL7
Interaction	KLF15 interactions	NCOA2 NIPBL EP300	1.44e-03	290	16	3	int:KLF15
Interaction	TLX3 interactions	NCOA2 NIPBL EP300	1.45e-03	291	16	3	int:TLX3
Interaction	TCF3 interactions	EP300 HMGCR SON	1.51e-03	295	16	3	int:TCF3
Interaction	DNAJC9 interactions	FOXA1 EP300 KAT6A	1.52e-03	296	16	3	int:DNAJC9
Interaction	DHX9 interactions	NIPBL EP300 KAT6A SON	1.53e-03	662	16	4	int:DHX9
Interaction	TSG101 interactions	PKNOX2 LAMC1 EP300	1.63e-03	303	16	3	int:TSG101
Interaction	SP7 interactions	NCOA2 NIPBL EP300	1.65e-03	304	16	3	int:SP7
Interaction	DDX56 interactions	FOXA1 EP300 KAT6A	1.65e-03	304	16	3	int:DDX56
Interaction	TACC2 interactions	FOXA1 EP300	1.67e-03	77	16	2	int:TACC2
Interaction	STK38L interactions	NIPBL KAT6A	1.67e-03	77	16	2	int:STK38L
Interaction	KHSRP interactions	NIPBL EP300 HMGCR	1.71e-03	308	16	3	int:KHSRP
Interaction	ING4 interactions	EP300 KAT6A	1.71e-03	78	16	2	int:ING4
Interaction	DNA2 interactions	EP300 HMGCR	1.76e-03	79	16	2	int:DNA2
Interaction	CHMP2B interactions	FOXA1 CHMP2B	1.76e-03	79	16	2	int:CHMP2B
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	NCOA2 EP300 KAT6A	1.51e-07	17	12	3	486
Coexpression	SCHLOSSER_SERUM_RESPONSE_DN	NCOA2 LAMC1 EP300 HMGCR CLINT1 CHMP2B	2.36e-06	705	16	6	M1410
Coexpression	WIEMANN_TELOMERE_SHORTENING_AND_CHRONIC_LIVER_DAMAGE_DN	HMGCR NR1D2	3.49e-06	5	16	2	M1244
Coexpression	WIEMANN_TELOMERE_SHORTENING_AND_CHRONIC_LIVER_DAMAGE_DN	HMGCR NR1D2	5.23e-06	6	16	2	MM971
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	NCOA2 LAMC1 NIPBL CLINT1 KAT6A SON	7.21e-06	856	16	6	M4500
Coexpression	LAIHO_COLORECTAL_CANCER_SERRATED_UP	LAMC1 CLINT1 CHMP2B	4.42e-05	115	16	3	M16586
Coexpression	KANG_DOXORUBICIN_RESISTANCE_DN	NFAT5 NR1D2	5.94e-05	19	16	2	M3323
Coexpression	NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_DN	NCOA2 NIPBL KAT6A SON	8.33e-05	399	16	4	M40939
Coexpression	HALLMARK_UV_RESPONSE_DN	LAMC1 NIPBL NR1D2	8.63e-05	144	16	3	M5942
Coexpression	NUYTTEN_NIPP1_TARGETS_DN	FOXA1 LAMC1 HMGCR CLINT1 NR1D2	1.12e-04	845	16	5	M18090
Coexpression	GAUTAM_EYE_CORNEA_FIBROBLASTS	NFAT5 LAMC1 SON	1.29e-04	165	16	3	M43617
Coexpression	LAKE_ADULT_KIDNEY_C11_THIN_ASCENDING_LIMB	NCOA2 NFAT5 NIPBL	1.39e-04	169	16	3	M39230
Coexpression	GSE7219_WT_VS_NIK_NFKB2_KO_DC_UP	NCOA2 LAMC1 HMGCR	1.81e-04	185	16	3	M377
Coexpression	GSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_NFATC1_KO_8H_UP	NIPBL NR1D2 KAT6A	2.02e-04	192	16	3	M8272
Coexpression	GSE22886_NAIVE_TCELL_VS_NKCELL_DN	NCOA2 NFAT5 NIPBL	2.21e-04	198	16	3	M4415
Coexpression	GSE22886_NAIVE_VS_IGG_IGA_MEMORY_BCELL_UP	LAMC1 NIPBL CHMP2B	2.21e-04	198	16	3	M4432
Coexpression	GSE41176_UNSTIM_VS_ANTI_IGM_STIM_TAK1_KO_BCELL_24H_DN	TBC1D30 NFAT5 CHMP2B	2.24e-04	199	16	3	M9920
Coexpression	GSE7764_IL15_NK_CELL_24H_VS_SPLENOCYTE_DN	NIPBL EP300 KAT6A	2.24e-04	199	16	3	M5726
Coexpression	GSE45881_CXCR6HI_VS_CXCR1LO_COLONIC_LAMINA_PROPRIA_UP	NCOA2 EP300 KAT6A	2.28e-04	200	16	3	M9889
Coexpression	GSE19888_ADENOSINE_A3R_INH_VS_ACT_WITH_INHIBITOR_PRETREATMENT_IN_MAST_CELL_UP	FOXA1 RYR2 KAT6A	2.28e-04	200	16	3	M7322
Coexpression	GSE40277_EOS_AND_LEF1_TRANSDUCED_VS_GATA1_AND_SATB1_TRANSDUCED_CD4_TCELL_UP	TBC1D30 LAMC1 RYR2	2.28e-04	200	16	3	M9169
Coexpression	GSE36888_UNTREATED_VS_IL2_TREATED_STAT5_AB_KNOCKIN_TCELL_2H_UP	TBC1D30 NFAT5 LAMC1	2.28e-04	200	16	3	M8733
Coexpression	ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_DN	MS4A4A NIPBL	2.97e-04	42	16	2	MM733
Coexpression	BENITEZ_GBM_PROTEASOME_INHIBITION_RESPONSE	EP300 HMGCR	3.88e-04	48	16	2	M40000
Coexpression	BROWNE_HCMV_INFECTION_10HR_DN	NIPBL SON	5.47e-04	57	16	2	M8416
Coexpression	NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN	EP300 NR1D2 KAT6A SON	6.37e-04	680	16	4	M41089
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_top-relative-expression-ranked_1000	TBC1D30 FOXA1 NCOA2 LAMC1 RYR2 SON	1.84e-05	818	16	6	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#4_top-relative-expression-ranked_1000	NCOA2 LAMC1 RYR2 SON	1.63e-04	385	16	4	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000_k4
CoexpressionAtlas	DevelopingLowerUrinaryTract_P1_bladder_J_emap-30374_k-means-cluster#1_top-relative-expression-ranked_1000	NFAT5 LAMC1 RYR2	1.77e-04	149	16	3	gudmap_developingLowerUrinaryTract_P1_bladder_J_1000_k1
CoexpressionAtlas	DevelopingLowerUrinaryTract_P1_bladder_J_emap-30374_top-relative-expression-ranked_1000	TBC1D30 FOXA1 NFAT5 LAMC1 RYR2	1.96e-04	772	16	5	gudmap_developingLowerUrinaryTract_P1_bladder_1000_J
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_top-relative-expression-ranked_500	TBC1D30 FOXA1 LAMC1 RYR2	2.29e-04	421	16	4	gudmap_developingLowerUrinaryTract_e14.5_ bladder_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_top-relative-expression-ranked_1000	TBC1D30 FOXA1 LAMC1 RYR2 SON	2.47e-04	811	16	5	gudmap_developingLowerUrinaryTract_e14.5_ bladder_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_top-relative-expression-ranked_200	FOXA1 LAMC1 RYR2	2.66e-04	171	16	3	gudmap_developingLowerUrinaryTract_e14.5_ bladder_200
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-6668_top-relative-expression-ranked_1000	TBC1D30 FOXA1 NFAT5 RYR2 SON	2.69e-04	826	16	5	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-6668_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_k-means-cluster#4_top-relative-expression-ranked_500	TBC1D30 FOXA1	4.94e-04	44	16	2	gudmap_developingLowerUrinaryTract_e14.5_ bladder_500_k4
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#5_top-relative-expression-ranked_500	TBC1D30 FOXA1	5.64e-04	47	16	2	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_500_k5
ToppCell	droplet-Marrow-nan-3m-Myeloid-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NIPBL EP300 CLINT1 KAT6A	4.54e-07	182	16	4	f8c73baaaca145e2efc48f10f636feb79c8fc779
ToppCell	droplet-Marrow-nan-3m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NIPBL EP300 CLINT1 KAT6A	4.74e-07	184	16	4	1154a5ad7b8512272b7476f949ddac350910bfb7
ToppCell	droplet-Marrow-nan-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NIPBL EP300 CLINT1 KAT6A	4.85e-07	185	16	4	7adfa929930cfa795cbfbd9f1a0b439e08aa765d
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	3.45e-05	181	16	3	9ede19228ba5c0668a9c06c915510b95585216ef
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1\|TCGA-Pancreas / Sample_Type by Project: Shred V9	NCOA2 NFAT5 EP300	3.74e-05	186	16	3	03db813598b67b1e08f759758a1c2023396921fa
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D175\|Adult / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	3.80e-05	187	16	3	e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 LAMC1 RYR2	4.05e-05	191	16	3	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 LAMC1 RYR2	4.11e-05	192	16	3	99ce9e3c4c50cf64ebb62145f2b5420efa0db309
ToppCell	Mesenchymal-matrix_fibroblast_1_cell\|World / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.18e-05	193	16	3	acad568621ed677031797b8c2e34dafea798d681
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.18e-05	193	16	3	99525545552b371c86b18b6ea6f4897dc6e9a9ec
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.18e-05	193	16	3	b3ad5ff480d99217f36cc7471e5a96a519ddb409
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.24e-05	194	16	3	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	Control-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	PKNOX2 LAMC1 RYR2	4.24e-05	194	16	3	3c2266772c5b56e8e02a461e5193e29588028ee9
ToppCell	droplet-Limb_Muscle-MUSCLE\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NIPBL NR1D2 SON	4.24e-05	194	16	3	e3d63874111d1e8da3977329426e4dcf68d6de87
ToppCell	Control-Stromal-Myofibroblast\|Control / Disease state, Lineage and Cell class	PKNOX2 LAMC1 RYR2	4.31e-05	195	16	3	ffcf76cd72e43d8cf1058a49c76e0956065038bc
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell\|Adult / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.31e-05	195	16	3	61c9e09fc84d1012e472185d70ad0a06cee30d6e
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	PKNOX2 LAMC1 RYR2	4.31e-05	195	16	3	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D122\|Adult / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.31e-05	195	16	3	aa0add081881d349099d12efca5cdee098038d4e
ToppCell	COPD-Stromal-Myofibroblast\|COPD / Disease state, Lineage and Cell class	PKNOX2 LAMC1 RYR2	4.37e-05	196	16	3	af206bb5bbb8b604a6212acd79878bcc3d326cec
ToppCell	Children_(3_yrs)-Mesenchymal\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.37e-05	196	16	3	bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCell	nucseq-Mesenchymal-Fibroblastic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 LAMC1 RYR2	4.37e-05	196	16	3	7d8505dac15fa59935ccf592afc54b04c4c6554f
ToppCell	COVID-19-Fibroblasts\|COVID-19 / group, cell type (main and fine annotations)	PKNOX2 LAMC1 RYR2	4.44e-05	197	16	3	fb847f2277609c31fffcdf49517243ce0684facf
ToppCell	COPD-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	PKNOX2 LAMC1 RYR2	4.44e-05	197	16	3	d51f484b4e01ac64233950d0b97fa88825ea1dbb
ToppCell	nucseq-Mesenchymal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 LAMC1 RYR2	4.51e-05	198	16	3	8f52243ca8b9ba68a75ae411506a3a6de258eb97
ToppCell	COVID-19-lung-Fibroblast\|lung / Disease (COVID-19 only), tissue and cell type	PKNOX2 LAMC1 RYR2	4.51e-05	198	16	3	df3de77216f5c5d6141ec44d01c56b942f611838
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PKNOX2 LAMC1 RYR2	4.51e-05	198	16	3	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	Adult-Mesenchymal\|Adult / Lineage, Cell type, age group and donor	PKNOX2 LAMC1 RYR2	4.51e-05	198	16	3	26e55b409db2a1637c95fae7c54b0abea1ef550c
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	PKNOX2 HMGCR RYR2	4.57e-05	199	16	3	8b86c69aaf60feff53aa782559cfece7342a23de
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	NIPBL CLINT1 SON	4.64e-05	200	16	3	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	(08)_Brush+PNEC-(2)_GFP_FOXI1\|(08)_Brush+PNEC / shred by cell type by condition	NIPBL CLINT1	1.09e-03	138	16	2	817e3f639604ea95adae01e8685ffaa2e0aff7a8
ToppCell	367C-Epithelial_cells-Epithelial-D_(AT2)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	TBC1D30 HMGCR	1.14e-03	141	16	2	f3b1d757c4cac8596c542959c8f27f8bcaf3f513
ToppCell	367C-Epithelial_cells-Epithelial-D_(AT2)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	TBC1D30 HMGCR	1.14e-03	141	16	2	bf68a54e755cda89fbc416636e522cd71d1e42d0
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Macrophage-macrophage,_alveolar-Macro_c1-C1QC\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	PKNOX2 MS4A4A	1.19e-03	144	16	2	f769be4da268980ea7c06d7097ec39d06777e675
ToppCell	COVID-19-kidney-Technical/muscle_(PCT)\|kidney / Disease (COVID-19 only), tissue and cell type	FOXA1 RYR2	1.22e-03	146	16	2	c55f1bdb6ac43b4118cb27ea7c879527e1afcbab
ToppCell	facs-Lung-3m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CLINT1 RYR2	1.25e-03	148	16	2	5983c4546f527a0b599cfcbd8a6cb937a1d6f895
ToppCell	TCGA-Thymus-Primary_Tumor-Thymoma-Type_C-8\|TCGA-Thymus / Sample_Type by Project: Shred V9	TBC1D30 FOXA1	1.37e-03	155	16	2	00eef9f93a753a1fe1ab5fd8dae026e7be556cde
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PKNOX2 RYR2	1.39e-03	156	16	2	6365b69ede98bc866e996bc52736b00401aacf6f
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic-Pericyte_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PKNOX2 RYR2	1.41e-03	157	16	2	bfec34182f052cf1c0d847ba53ea335d4d1190de
ToppCell	Fetal_29-31_weeks-Epithelial-club_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	FOXA1 CLINT1	1.50e-03	162	16	2	5c9bc3c3857a99d8a3caf359a7eb279ce9cc1c81
ToppCell	TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Diffuse-6\|TCGA-Stomach / Sample_Type by Project: Shred V9	CLINT1 CHMP2B	1.51e-03	163	16	2	c1a98d6776b685f20dde049715233e5c73ce3244
ToppCell	TCGA-Thymus-Primary_Tumor-Thymoma-Type_C\|TCGA-Thymus / Sample_Type by Project: Shred V9	TBC1D30 FOXA1	1.51e-03	163	16	2	2dac87d15051151ccf193760ddd8b82534c3f922
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.55e-03	165	16	2	8a82e20c9b1156bb4bbc16f7785abb04458d671b
ToppCell	COVID-19-Heart-CM_+_Macrophage\|Heart / Disease (COVID-19 only), tissue and cell type	MS4A4A RYR2	1.64e-03	170	16	2	4232fe937909f93d3736988c707b8f95ce993398
ToppCell	Control-Fibroblasts-Pericytes\|Control / group, cell type (main and fine annotations)	PKNOX2 RYR2	1.66e-03	171	16	2	080003f698f867935c2bfc55d241d3650f45a0ab
ToppCell	Adult-Mesenchymal-pericyte_cell-D231\|Adult / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.68e-03	172	16	2	858cee96c1c06160863b4adcd7023c0d678bd50f
ToppCell	Adult-Mesenchymal-pericyte_cell-D175\|Adult / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.70e-03	173	16	2	fd6653d6be9ca6ac36798590694efe03cb758c67
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.70e-03	173	16	2	5416b092321c7d9b63f0418c60f2402a138355bf
ToppCell	Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.72e-03	174	16	2	015d3742d3d79a57413a333f00ef2d380a9848dd
ToppCell	(03)_Secretory-(4)_1wkpi\|(03)_Secretory / shred by cell type and Timepoint	NFAT5 NR1D2	1.74e-03	175	16	2	06b52f85baa31b55bb31477244892b6da79fe2c9
ToppCell	CV-Severe-7\|CV / Virus stimulation, Condition and Cluster	NFAT5 HMGCR	1.76e-03	176	16	2	3de0c7d77210049e5616db21eed1490a17a5ec2d
ToppCell	droplet-Tongue-nan-24m\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CLINT1 SON	1.76e-03	176	16	2	9739b0653c511ab017507a0c7ee4f6d7082e87db
ToppCell	CV-Severe-7\|Severe / Virus stimulation, Condition and Cluster	NFAT5 HMGCR	1.78e-03	177	16	2	82fdd6185b368f54f03de389427cbe3071d21a99
ToppCell	343B-Fibroblasts-Fibroblast-B_(Myofibroblast)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	PKNOX2 RYR2	1.78e-03	177	16	2	43ba6f12c2fb32698a420bf799d46ac1b558f146
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PKNOX2 RYR2	1.78e-03	177	16	2	9ec7f1e64312d26d434b3312b58386715dbad644
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PKNOX2 RYR2	1.78e-03	177	16	2	016277dfd59b1793fddaaadc2b3f41622d76ce3a
ToppCell	343B-Fibroblasts-Fibroblast-B_(Myofibroblast)\|343B / Donor, Lineage, Cell class and subclass (all cells)	PKNOX2 RYR2	1.78e-03	177	16	2	e55d21d4d61a069b9bbe0e7595fbfb7cfbacfd87
ToppCell	Endothelial-Endothelial-C\|Endothelial / shred on cell class and cell subclass (v4)	PKNOX2 SON	1.78e-03	177	16	2	b5b9278dfd76b1aacd88e5fe86e91a2c9b565f87
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.80e-03	178	16	2	185b44700f06ec58b3c09c80520502166c965fd6
ToppCell	cellseq2-Mesenchymal-Fibroblastic-Fibroblastic_2-ASMC\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 RYR2	1.80e-03	178	16	2	8ec2a25dda96c9cc9c2904b6cb18f75a293f4969
ToppCell	cellseq2-Mesenchymal-Fibroblastic-Fibroblastic_2\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 RYR2	1.80e-03	178	16	2	6c91331196696e0cf239d105f458e3230659fa38
ToppCell	facs-Heart-RA-18m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FOXA1 CLINT1	1.80e-03	178	16	2	b505e2550860e777535ee95f29c936242fd607f1
ToppCell	droplet-Tongue-nan-24m-Epithelial\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CLINT1 SON	1.80e-03	178	16	2	a3176b2b335db22bb0fb71aafa5d7a287809396e
ToppCell	10x5'-lymph-node_spleen-Myeloid_Mac-Intestinal_macrophages\|lymph-node_spleen / Manually curated celltypes from each tissue	TBC1D30 MS4A4A	1.84e-03	180	16	2	7be7d7a6906fff6dbdecd9cb013d855aba4eda2a
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-5\|TCGA-Colorectal / Sample_Type by Project: Shred V9	FOXA1 CLINT1	1.86e-03	181	16	2	8fcc9e77fee7c248df26b6c59b10e672242e2084
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.86e-03	181	16	2	451b87ac95154bb80018b8dd245b4a6389d81411
ToppCell	COVID-19-Heart-Fib_+_EC_+_Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PKNOX2 LAMC1	1.88e-03	182	16	2	fbd5e332df73bf7141c822fa67b76367dc962017
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PKNOX2 RYR2	1.90e-03	183	16	2	8a799807fbf24456a9811e0c64068187940a2f71
ToppCell	Adult-Mesenchymal-pericyte_cell-D122\|Adult / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.90e-03	183	16	2	fc31a43a637423cb3bb9aa184a3a889a0b9aaea6
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PKNOX2 RYR2	1.92e-03	184	16	2	689a8af81a79a4bb3123cfa01958c953eab5de98
ToppCell	COVID-19-Fibroblasts-Pericytes\|COVID-19 / group, cell type (main and fine annotations)	PKNOX2 RYR2	1.94e-03	185	16	2	4905adaeeffd353e089578e5ea614437dbe794e6
ToppCell	COVID-19-Heart-Fib_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PKNOX2 LAMC1	1.94e-03	185	16	2	8f95d8e591bf7379d13f5a0545b0cb49e2b1ab5d
ToppCell	3'-Airway_Nasal_SMG-Epithelial-Epithelial_transtional-secretory-SMG_mucus_secreting_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FOXA1 RYR2	1.94e-03	185	16	2	d9039770226338fbc3fce92aa229fad96e16db8c
ToppCell	3'-Airway_Nasal_SMG-Epithelial-Epithelial_transtional-secretory-SMG_mucus_secreting_cell-SMG_mucous\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FOXA1 RYR2	1.94e-03	185	16	2	b931ab35da10e6e3877071dce9b13fc0da63dc88
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	NFAT5 HMGCR	1.94e-03	185	16	2	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.94e-03	185	16	2	a7dba7db79275884b2a93d8a16f2e0c739e71370
ToppCell	COPD-Stromal-Pericyte\|World / Disease state, Lineage and Cell class	PKNOX2 RYR2	1.96e-03	186	16	2	8adfd2d1fda4e8aecc95192ea627bf7ed5214b8d
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	PKNOX2 RYR2	1.96e-03	186	16	2	7def03dd856b765bd3f493288641981c4f7fd26e
ToppCell	368C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	TBC1D30 FOXA1	1.98e-03	187	16	2	61c00604dda8b36a5c3eea6554e5601aa1b884f7
ToppCell	saliva-Mild-Moderate_progression_d12-25-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	FOXA1 NR1D2	1.98e-03	187	16	2	43ef900b76f3c38bd8ce9858201124130c743d56
ToppCell	droplet-Bladder-nan\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NIPBL SON	1.98e-03	187	16	2	663991a8afe652e92363b64bcbd68c14d0307f0e
ToppCell	Adult-Mesenchymal-pericyte_cell\|Adult / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.98e-03	187	16	2	62759efb660179402fb574ce5701c89a2e17bcfe
ToppCell	saliva-Mild-Moderate_progression_d12-25-Epithelial-Epithelial,_Airway-secretory_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	FOXA1 NR1D2	1.98e-03	187	16	2	6e5c38425b6b1d4774f8dcea7e146f1eab785c3e
ToppCell	368C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)\|368C / Donor, Lineage, Cell class and subclass (all cells)	TBC1D30 FOXA1	1.98e-03	187	16	2	b827d9da7032bf051756ddf88352af922eb0f87b
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.98e-03	187	16	2	a2bf958ea59c359a265bfa437d59315e1920cdd4
ToppCell	Control-Fibroblasts-Alveolar_FB\|Control / group, cell type (main and fine annotations)	PKNOX2 RYR2	1.98e-03	187	16	2	92d468dde81125d51daf7abd4703741abe1ab91c
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 RYR2	1.98e-03	187	16	2	86250acf088ec0c4800a0dfa031b0d4f7e52c342
ToppCell	facs-Pancreas-Endocrine-24m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HMGCR SON	2.01e-03	188	16	2	a91443aa8fa8fa87f7501c59219daa0305bd0bbf
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PKNOX2 RYR2	2.01e-03	188	16	2	ee151792c7ac9afe820f1a281c6dab383799f358
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	NFAT5 NIPBL	2.01e-03	188	16	2	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	ILEUM-non-inflamed-(5)_Plasma-(5)_IgG_plasma_cells\|(5)_Plasma / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	CLINT1 SON	2.01e-03	188	16	2	2156f1bc849ff1cb09ae296d13bedd913ae6b43b
ToppCell	droplet-Tongue-nan\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NIPBL SON	2.01e-03	188	16	2	d62cc37e86b7b186e53aeb7f421c4e5ee28f23bd
ToppCell	Mesenchymal-pericyte_cell\|World / Lineage, Cell type, age group and donor	PKNOX2 RYR2	2.03e-03	189	16	2	d7ed96add29f219183c802895fbff519b627f635
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_pericyte_(14)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	PKNOX2 RYR2	2.03e-03	189	16	2	9c2492c38f27e4c699b40680652e4c64911cce52
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	NCOA2 NFAT5	2.03e-03	189	16	2	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PKNOX2 RYR2	2.03e-03	189	16	2	2a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_1-Pericyte\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 RYR2	2.05e-03	190	16	2	4eb92aef1ee868f4537483d19014d947b7684612
ToppCell	PND10\|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KAT6A SON	2.05e-03	190	16	2	d67e2814047c8df2ae4b7bc8be9539f5df6ecef2
ToppCell	Control-Fibroblasts\|Control / group, cell type (main and fine annotations)	PKNOX2 RYR2	2.05e-03	190	16	2	3a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PKNOX2 RYR2	2.05e-03	190	16	2	7be4341e2909101d756f14031c21e705eb45e69a
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_pericyte_(14)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	PKNOX2 RYR2	2.05e-03	190	16	2	10125091ad648163777b02e9f0d5e8d7f17d44a5
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA	TBC1D30 NCOA2 NIPBL EP300 SON	9.48e-08	172	16	5	1072_DN
Drug	Strophantine octahydrate [11018-89-6]; Up 200; 5.4uM; HL60; HT_HG-U133A	NFAT5 NIPBL KAT6A SON	5.58e-06	174	16	4	1302_UP
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A	NFAT5 NR1D2 CHMP2B SON	6.25e-06	179	16	4	4585_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NIPBL SON	6.67e-06	182	16	4	3887_DN
Drug	AR45	NCOA2 HMGCR	6.93e-06	6	16	2	CID000111148
Drug	tyrphostin AG-825; Down 200; 25.2uM; MCF7; HT_HG-U133A_EA	NCOA2 NIPBL HMGCR SON	7.12e-06	185	16	4	1114_DN
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; PC3; HT_HG-U133A	TBC1D30 NCOA2 NFAT5 KAT6A	7.91e-06	190	16	4	4507_DN
Drug	Flunisolide [3385-03-3]; Down 200; 9.2uM; PC3; HT_HG-U133A	NCOA2 NFAT5 NR1D2 KAT6A	8.07e-06	191	16	4	4303_DN
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	NCOA2 NFAT5 NR1D2 KAT6A	8.07e-06	191	16	4	4279_DN
Drug	(-) -Levobunolol hydrochloride [27912-14-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NFAT5 RYR2	8.58e-06	194	16	4	4134_DN
Drug	Riluzole hydrochloride; Down 200; 14.8uM; MCF7; HT_HG-U133A	TBC1D30 NFAT5 RYR2 KAT6A	8.94e-06	196	16	4	4689_DN
Drug	Chlorogenic acid [327-97-9]; Down 200; 11.2uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 RYR2 KAT6A	9.30e-06	198	16	4	1346_DN
Drug	Biotin [58-85-5]; Down 200; 16.4uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 NFAT5 KAT6A	9.30e-06	198	16	4	2428_DN
Drug	Dapsone [80-08-0]; Up 200; 16.2uM; MCF7; HT_HG-U133A	LAMC1 EP300 RYR2 SON	9.49e-06	199	16	4	1705_UP
Drug	AC1N0FHX	EP300 KAT6A	1.29e-05	8	16	2	CID003916227
Drug	AC1L9FY1	NCOA2 NFAT5 EP300	4.55e-05	101	16	3	CID000444218
Drug	pyrraline	HMGCR RYR2	4.84e-05	15	16	2	CID000122228
Drug	Chenodeoxycholic Acid	NCOA2 HMGCR NR1D2	5.40e-05	107	16	3	ctd:D002635
Drug	Dihydrotestosterone	FOXA1 NCOA2 LAMC1 EP300	9.63e-05	360	16	4	ctd:D013196
Drug	ML-236A	HMGCR CLINT1 CHMP2B	1.06e-04	134	16	3	CID000173651
Drug	geldanamycin	NCOA2 NFAT5 NIPBL KAT6A	1.08e-04	371	16	4	ctd:C001277
Drug	perfluorooctane sulfonate	NCOA2 HMGCR	1.16e-04	23	16	2	CID000074483
Drug	thioridazine hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A	EP300 HMGCR NR1D2	1.85e-04	162	16	3	1655_UP
Drug	Digitoxigenin [143-62-4]; Up 200; 10.6uM; HL60; HT_HG-U133A	NFAT5 KAT6A SON	1.85e-04	162	16	3	1339_UP
Drug	Methylene Chloride	FOXA1 NFAT5 NR1D2	1.88e-04	163	16	3	ctd:D008752
Drug	Lanatoside C [17575-22-3]; Up 200; 4uM; MCF7; HT_HG-U133A	NFAT5 KAT6A SON	1.92e-04	164	16	3	3852_UP
Drug	anacardic acid	EP300 KAT6A	1.99e-04	30	16	2	CID000167551
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	TBC1D30 NCOA2 EP300	2.13e-04	170	16	3	1050_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 EP300	2.24e-04	173	16	3	5987_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NIPBL	2.28e-04	174	16	3	7530_DN
Drug	SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA	TBC1D30 NCOA2 EP300	2.32e-04	175	16	3	1058_DN
Drug	SAHA; Down 200; 10uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 EP300	2.40e-04	177	16	3	1645_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 NIPBL NR1D2	2.40e-04	177	16	3	6972_DN
Drug	Atovaquone [95233-18-4]; Down 200; 11uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 HMGCR	2.40e-04	177	16	3	2480_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 EP300	2.40e-04	177	16	3	6434_DN
Drug	Etifenin [63245-28-3]; Down 200; 12.4uM; PC3; HT_HG-U133A	NFAT5 NR1D2 SON	2.44e-04	178	16	3	3998_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	NCOA2 NIPBL EP300	2.48e-04	179	16	3	5822_DN
Drug	glutamin	NFAT5 EP300 KAT6A CHMP2B	2.49e-04	461	16	4	CID000000738
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	NIPBL EP300 KAT6A	2.52e-04	180	16	3	4541_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 EP300	2.52e-04	180	16	3	4821_DN
Drug	B on A	NCOA2 EP300 KAT6A SON	2.55e-04	464	16	4	CID000007104
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	NCOA2 NIPBL EP300	2.56e-04	181	16	3	6951_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NIPBL	2.65e-04	183	16	3	7498_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NIPBL	2.69e-04	184	16	3	2321_DN
Drug	Corticosterone [50-22-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A	HMGCR RYR2 KAT6A	2.69e-04	184	16	3	3244_UP
Drug	Sulfaphenazole [526-08-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A	NFAT5 NR1D2 SON	2.73e-04	185	16	3	1673_DN
Drug	Benzene	NFAT5 HMGCR NR1D2 KAT6A SON	2.78e-04	892	16	5	ctd:D001554
Drug	Apigenin [520-36-5]; Down 200; 14.8uM; MCF7; HT_HG-U133A	TBC1D30 NFAT5 NIPBL	2.87e-04	188	16	3	3257_DN
Drug	Chlorpromazine hydrochloride [69-09-0]; Up 200; 11.2uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 HMGCR	2.91e-04	189	16	3	1700_UP
Drug	thioridazine hydrochloride; Down 200; 10uM; HL60; HT_HG-U133A	TBC1D30 NR1D2 KAT6A	2.91e-04	189	16	3	1171_DN
Drug	LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA	TBC1D30 LAMC1 NIPBL	2.91e-04	189	16	3	1065_DN
Drug	Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A	NFAT5 CLINT1 KAT6A	2.91e-04	189	16	3	3788_DN
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A	NFAT5 NIPBL HMGCR	2.96e-04	190	16	3	2619_DN
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; PC3; HT_HG-U133A	NFAT5 NR1D2 KAT6A	2.96e-04	190	16	3	4306_DN
Drug	Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; PC3; HT_HG-U133A	NCOA2 NFAT5 KAT6A	2.96e-04	190	16	3	4322_DN
Drug	tetrahydrocurcumin	EP300 HMGCR	3.04e-04	37	16	2	CID000124072
Drug	clozapine; Down 200; 10uM; HL60; HT_HG-U133A	TBC1D30 NFAT5 RYR2	3.05e-04	192	16	3	6188_DN
Drug	Methantheline bromide [53-46-3]; Down 200; 9.6uM; MCF7; HT_HG-U133A	NFAT5 EP300 CLINT1	3.05e-04	192	16	3	6254_DN
Drug	Nimodipine [66085-59-4]; Down 200; 9.6uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 RYR2	3.10e-04	193	16	3	3103_DN
Drug	0316684-0000 [391209-55-5]; Down 200; 10uM; MCF7; HT_HG-U133A	NCOA2 RYR2 NR1D2	3.10e-04	193	16	3	7052_DN
Drug	Antimycin A [1397-94-0]; Down 200; 7.2uM; PC3; HT_HG-U133A	TBC1D30 NIPBL EP300	3.10e-04	193	16	3	2098_DN
Drug	Carbarsone [121-59-5]; Up 200; 15.4uM; MCF7; HT_HG-U133A	NCOA2 NFAT5 KAT6A	3.10e-04	193	16	3	3250_UP
Drug	Terconazole [67915-31-5]; Up 200; 7.6uM; PC3; HT_HG-U133A	TBC1D30 NCOA2 PKNOX2	3.10e-04	193	16	3	4583_UP
Drug	Etofylline [519-37-9]; Down 200; 17.8uM; HL60; HG-U133A	NCOA2 NIPBL CHMP2B	3.14e-04	194	16	3	1409_DN
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A	NCOA2 NR1D2 SON	3.14e-04	194	16	3	4361_DN
Drug	Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A	NFAT5 NIPBL NR1D2	3.14e-04	194	16	3	3274_DN
Drug	Cephalothin sodium salt [58-71-9]; Down 200; 9.6uM; HL60; HT_HG-U133A	NCOA2 NFAT5 LAMC1	3.19e-04	195	16	3	2517_DN
Drug	Clozapine [5786-21-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	NCOA2 PKNOX2 RYR2	3.19e-04	195	16	3	5265_UP
Drug	Proadifen hydrochloride [62-68-0]; Down 200; 10.2uM; HL60; HT_HG-U133A	NCOA2 RYR2 KAT6A	3.19e-04	195	16	3	2707_DN
Drug	ICI182,780; Up 200; 1uM; PC3; HT_HG-U133A	TBC1D30 NCOA2 NR1D2	3.19e-04	195	16	3	6918_UP
Drug	Amitryptiline hydrochloride [549-18-8]; Up 200; 12.8uM; MCF7; HT_HG-U133A	PKNOX2 HMGCR NR1D2	3.19e-04	195	16	3	1701_UP
Drug	Hippeastrine hydrobromide [22352-41-6]; Down 200; 10uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 NFAT5	3.19e-04	195	16	3	2187_DN
Drug	Alfaxalone [23930-19-0]; Down 200; 12uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 NIPBL	3.19e-04	195	16	3	3135_DN
Drug	Betazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A	TBC1D30 RYR2 KAT6A	3.24e-04	196	16	3	6344_UP
Drug	Canrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; PC3; HT_HG-U133A	NIPBL EP300 NR1D2	3.24e-04	196	16	3	2065_DN
Drug	Isoniazid [54-85-3]; Up 200; 29.2uM; HL60; HG-U133A	NFAT5 NIPBL EP300	3.24e-04	196	16	3	1399_UP
Drug	Acetazolamide [59-66-5]; Up 200; 18uM; MCF7; HT_HG-U133A	NCOA2 RYR2 NR1D2	3.24e-04	196	16	3	1686_UP
Drug	Mefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; PC3; HT_HG-U133A	TBC1D30 NFAT5 RYR2	3.24e-04	196	16	3	2121_DN
Drug	Zidovudine, AZT [30516-87-1]; Down 200; 15uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NIPBL	3.24e-04	196	16	3	5333_DN
Drug	Clemizole hydrochloride [1163-36-6]; Up 200; 11uM; PC3; HT_HG-U133A	TBC1D30 PKNOX2 RYR2	3.24e-04	196	16	3	7371_UP
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; PC3; HT_HG-U133A	TBC1D30 RYR2 KAT6A	3.24e-04	196	16	3	3762_DN
Drug	Diltiazem hydrochloride [33286-22-5]; Down 200; 8.8uM; PC3; HG-U133A	NCOA2 NIPBL SON	3.24e-04	196	16	3	1948_DN
Drug	PNU-0230031 [267429-39-0]; Up 200; 1uM; PC3; HT_HG-U133A	TBC1D30 PKNOX2 KAT6A	3.24e-04	196	16	3	4291_UP
Drug	Metanephrine hydrochloride DL [881-95-8]; Up 200; 17.2uM; HL60; HG-U133A	NCOA2 LAMC1 EP300	3.24e-04	196	16	3	2015_UP
Drug	Ergocryptine-alpha [511-09-1]; Down 200; 7uM; MCF7; HT_HG-U133A	NFAT5 NIPBL NR1D2	3.24e-04	196	16	3	4374_DN
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A	NFAT5 NIPBL HMGCR	3.29e-04	197	16	3	1800_UP
Drug	Kaempferol [520-18-3]; Down 200; 14uM; MCF7; HT_HG-U133A	NCOA2 NFAT5 KAT6A	3.29e-04	197	16	3	3579_DN
Drug	Clozapine [5786-21-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NFAT5	3.29e-04	197	16	3	2644_DN
Drug	Monocrotaline [315-22-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	PKNOX2 NFAT5 RYR2	3.29e-04	197	16	3	2749_UP
Drug	Carcinine [56897-53-1]; Up 200; 22uM; MCF7; HT_HG-U133A	NCOA2 RYR2 KAT6A	3.29e-04	197	16	3	3242_UP
Drug	Ioxaglic acid [59017-64-0]; Down 200; 3.2uM; MCF7; HT_HG-U133A	EP300 RYR2 KAT6A	3.29e-04	197	16	3	3528_DN
Drug	Canrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; MCF7; HT_HG-U133A	TBC1D30 NCOA2 NFAT5	3.29e-04	197	16	3	2228_DN
Drug	Etoposide [33419-42-0]; Down 200; 6.8uM; PC3; HT_HG-U133A	TBC1D30 NCOA2 NIPBL	3.34e-04	198	16	3	6681_DN
Drug	9-deoxy-9-methylene-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; MCF7; HT_HG-U133A	NCOA2 PKNOX2 KAT6A	3.34e-04	198	16	3	7500_DN
Drug	Enalapril maleate [76095-16-4]; Up 200; 8.2uM; MCF7; HT_HG-U133A	NFAT5 NIPBL EP300	3.34e-04	198	16	3	7428_UP
Drug	Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; HL60; HT_HG-U133A	TBC1D30 NCOA2 PKNOX2	3.34e-04	198	16	3	2578_UP
Drug	Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; PC3; HT_HG-U133A	TBC1D30 NFAT5 KAT6A	3.34e-04	198	16	3	4343_UP
Drug	Chlorpheniramine maleate [113-92-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A	TBC1D30 NFAT5 RYR2	3.34e-04	198	16	3	2217_DN
Drug	Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; PC3; HT_HG-U133A	NCOA2 RYR2 KAT6A	3.34e-04	198	16	3	3756_DN
Drug	Naringin hydrate [11032-30-7]; Down 200; 6.6uM; HL60; HT_HG-U133A	TBC1D30 NIPBL CLINT1	3.34e-04	198	16	3	2425_DN
Disease	Adenoid Cystic Carcinoma	EP300 KAT6A SON	2.05e-05	100	16	3	C0010606
Disease	Breast adenocarcinoma	FOXA1 EP300	2.23e-04	41	16	2	C0858252
Disease	Neoplasm of uncertain or unknown behavior of breast	FOXA1 EP300	2.23e-04	41	16	2	C0496956
Disease	Prostatic Neoplasms	FOXA1 NCOA2 LAMC1 KAT6A	2.80e-04	616	16	4	C0033578
Disease	Malignant neoplasm of prostate	FOXA1 NCOA2 LAMC1 KAT6A	2.80e-04	616	16	4	C0376358
Disease	acute myeloid leukemia (is_implicated_in)	NCOA2 KAT6A	9.36e-04	84	16	2	DOID:9119 (is_implicated_in)
Disease	response to antineoplastic agent	NFAT5 RYR2	1.30e-03	99	16	2	GO_0097327
Disease	mood instability measurement	LAMC1 EP300	2.15e-03	128	16	2	EFO_0008475
Disease	Malignant neoplasm of breast	FOXA1 NCOA2 NIPBL EP300	2.24e-03	1074	16	4	C0006142
Disease	Mammary Neoplasms, Human	FOXA1 NCOA2 EP300	2.64e-03	525	16	3	C1257931
Disease	Mammary Carcinoma, Human	FOXA1 NCOA2 EP300	2.64e-03	525	16	3	C4704874
Disease	stomach cancer (is_marker_for)	FOXA1 NCOA2	2.64e-03	142	16	2	DOID:10534 (is_marker_for)
Disease	Mammary Neoplasms	FOXA1 NCOA2 EP300	2.67e-03	527	16	3	C1458155

Protein segments in the cluster

Peptide	Gene	Start	Entry
MSPQAQQMNMNHNTM	EP300	2161	Q09472
VMNSQMKMAGAMSTT	CHMP2B	91	Q9UQN3
QATMTSSQSMNFSMM	CLINT1	431	Q14677
TLTICMMSMNMFTGN	HMGCR	26	P04035
SMQNRYVQSGMMMSQ	NIPBL	111	Q6KC79
MMMSQYKLSQNSMHS	NIPBL	121	Q6KC79
QQQVMESSAAMVMEM	NFAT5	886	O94916
SHMMSALSTNEDMQM	NFAT5	936	O94916
MNSMNTYMTMNTMTT	FOXA1	41	P55317
TQQMASMGSSCSMMQ	KAT6A	1606	Q92794
FSAAMTTMQGMEQAM	MS4A4A	16	Q96JQ5
MSLSMGITMMCMASN	MS4A4A	76	Q96JQ5
DADQDMMMAGMASQA	LAMC1	1481	P11047
MMMAGMASQAAQEAE	LAMC1	1486	P11047
MESNYVSMMEKQSSM	RYR2	2681	Q92736
DSATMAMQQAMMAAH	PKNOX2	411	Q96KN3
MQSAMKTMMNSQFSG	NR1D2	191	Q14995
MTNTTNQYSSLMIMM	MT-ND2	86	P03891
MSSMNQMTGQISMTS	NCOA2	1401	Q15596
NSMMMERMTTDINAL	TBC1D30	626	Q9Y2I9
MDSQMLASNTMDSQM	SON	731	P18583
MDSQMLASNTMDSQM	SON	741	P18583
MDSQMLASSTMDSQM	SON	751	P18583
MDSQMLATSSMDSQM	SON	761	P18583
MDSQMLATSSMDSQM	SON	771	P18583
MDSQMLATSTMDSQM	SON	781	P18583
MDSQMLATSSMDSQM	SON	791	P18583
MDSQMLATSSMDSQM	SON	801	P18583
MDSQMLATSSMDSQM	SON	811	P18583
MDSQMLATSSMDSQM	SON	821	P18583
MDSQMLATSTMDSQM	SON	831	P18583
MDSQMLATSTMDSQM	SON	841	P18583
MDSQMLATSSMDSQM	SON	851	P18583
MDSQMLASGTMDSQM	SON	861	P18583
MDSQMLASGTMDAQM	SON	871	P18583
MDAQMLASGTMDAQM	SON	881	P18583
MDAQMLASSTQDSAM	SON	891	P18583